AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie reported $61.2B FY2025 revenue (+~9% YoY) and $4.2B net income as it offsets Humira’s loss of exclusivity, while Pfizer posted ~$62.6B revenue (-~1.6% YoY) but $7.8B net income (+vs. two years prior) amid post-COVID normalization. Valuation is more favorable for Pfizer (Forward P/E 9.8x vs. AbbVie 16.1x; P/S 2.6x vs. 7.2x) as both firms face patent-expiration and drug-pricing reform risks, including Inflation Reduction Act price setting. Near-term growth expectations are stronger for AbbVie (net income forecast $4.2B to $14.6B; sales $67.2B) versus Pfizer’s ~40% FY2026 net income jump to $11B+ (sales $61.7B).

Analysis

The market is not being asked to choose between quality and value so much as between visible cash conversion and distant optionality. ABBV’s edge is that its growth is already showing up in free cash flow, which matters more in a higher-for-longer rate regime where leverage and dividend durability are re-rated daily. PFE looks optically cheap, but cheap multiples can persist for years when the earnings base is still drifting lower and the pipeline needs multiple binary wins to change the narrative.

The second-order issue is competitive positioning: ABBV’s continued self-funded M&A and immunology dominance raise the bar for smaller biotech assets and keep acquisition multiples elevated across the space, but they also make ABBV more sensitive to any slowdown in its two-drug franchise. For PFE, the real risk is not one patent expiry but the possibility that capital allocation into pipeline deals becomes a capital sink if oncology and obesity readouts fail to validate the spend. That would pressure the stock multiple even if reported EPS temporarily stabilizes.

Catalyst timing matters. Over the next 1-3 months, earnings guidance and regulatory cadence will matter more than headline valuation; over 6-18 months, the relative path will be decided by whether ABBV can keep organic growth above mid-single digits and whether PFE can convert pipeline optionality into revenue visibility. The contrarian view is that the consensus may be underestimating ABBV’s quality premium: in pharma, cash flow durability usually deserves a richer multiple than a low-P/E stock with a long patent cliff and uncertain replacement assets.

Key Decisions for Investors

• Initiate a beta-neutral long ABBV / short PFE pair for 6-12 months; enter on any post-earnings volatility or 3-5% pullback in ABBV. Target relative outperformance if ABBV retains mid-single-digit organic growth; cover if ABBV guidance de-rates or PFE posts a materially positive late-stage readout.
• If taking outright exposure, prefer ABBV over PFE in healthcare income baskets. The risk/reward is better tied to already-monetized growth rather than pipeline hope, though the thesis fails if ABBV’s two-drug concentration starts to compress faster than expected.
• Use PFE only as a catalyst trade, not a core holding, until there is evidence of a revenue inflection from oncology/obesity assets. A long-dated call spread is only justified if the next 2-3 clinical/FDA events materially narrow the patent-cliff overhang.
• Watch APGE as a read-through on what ABBV is willing to pay for immunology optionality; if biotech M&A multiples keep rising, late-stage single-asset names become takeover-sensitive but also more vulnerable to disappointment if deal premiums stop expanding.